IFRX Stock - InflaRx N.V.
Unlock GoAI Insights for IFRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $165,789 | $63,089 | N/A | N/A | N/A |
| Gross Profit | $-3,151,250 | $-469,173 | $-627,008 | $-791,258 | $-812,474 |
| Gross Margin | -1900.8% | -743.7% | N/A | N/A | N/A |
| Operating Income | $-53,008,864 | $-44,908,096 | $-55,066,486 | $-56,359,990 | $-38,931,657 |
| Net Income | $-46,064,402 | $-42,667,529 | $-30,987,568 | $-53,933,859 | $-38,740,450 |
| Net Margin | -27785.0% | -67630.7% | N/A | N/A | N/A |
| EPS | $-0.78 | $-0.78 | $-0.61 | $-1.10 | $-1.26 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Leerink Partners | Downgrade | Market Perform | $2 |
| September 2nd 2025 | H.C. Wainwright | Resumed | Buy | $6 |
| May 29th 2025 | Raymond James | Downgrade | Outperform | $2 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $10 |
| April 5th 2023 | Guggenheim | Upgrade | Buy | $8 |
Earnings History & Surprises
IFRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.17 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.16 | $-0.16 | 0.0% | = MET |
Q3 2025 | Aug 7, 2025 | $-0.24 | $-0.24 | 0.0% | = MET |
Q2 2025 | May 7, 2025 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.27 | $-0.09 | +66.7% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.27 | $-0.33 | -22.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.21 | $-0.26 | -23.8% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.24 | $-0.19 | +20.8% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.20 | $-0.30 | -50.0% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.29 | $-0.14 | +51.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.36 | $-0.15 | +58.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $0.25 | $-0.18 | -172.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.36 | $-0.18 | +50.0% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $-0.34 | $0.01 | +102.9% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.34 | $-0.36 | -5.9% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.37 | $-0.33 | +10.8% | ✓ BEAT |
Q4 2021 | Nov 5, 2021 | $-0.37 | $-0.32 | +13.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.25 | $-0.40 | -60.0% | ✗ MISS |
Latest News
InflaRx Receives WHO International Nonproprietary Name Izicopan For Oral C5aR Inhibitor INF904 Following Encouraging Data In Hidradenitis Suppurativa And Chronic Spontaneous Urticaria
📈 PositiveLeerink Partners Downgrades InflaRx to Market Perform, Lowers Price Target to $2
📉 NegativeInflaRx shares are trading higher after Guggenheim raised its price target on the stock from $10 to $22 while maintaining a Buy rating.
📈 PositiveGuggenheim Maintains Buy on InflaRx, Raises Price Target to $22
📈 PositiveInflaRx Presents Phase 2a INF904 Data In Hidradenitis Suppurative And Chronic Spontaneous Urticaria
➖ NeutralInflaRx shares are trading higher after the company said it will present Phase 2a data for its oral C5aR inhibitor INF904 in two inflammatory skin diseases on Nov. 10.
📈 PositiveInflaRx To Present Data From Phase 2a Clinical Study Of Oral C5ar Inhibitor INF904 In Participants With Hidradenitis Suppurativa And Chronic Spontaneous Urticaria On Nov. 10
➖ NeutralInflaRx Regains Nasdaq Compliance
📈 PositiveHC Wainwright & Co. Assumes InflaRx at Buy, Announces Price Target of $6
📈 PositiveInflaRx plunges on plans to halt studies into lead asset in rare skin disorder
📉 NegativeFrequently Asked Questions about IFRX
What is IFRX's current stock price?
What is the analyst price target for IFRX?
What sector is InflaRx N.V. in?
What is IFRX's market cap?
Does IFRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IFRX for comparison